Global pricing strategies for innovative essential drugs

International Journal of Biotechnology

Volumn 3, Issue 3-4, 2001, Pages 338-349

  Dumoulin, Jérôme ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

Compulsory licensing; Discrimination prices; Parallel imports; Pharmaceuticals

Indexed keywords

COMPUTER SIMULATION; DRUG PRODUCTS; ENGINEERING RESEARCH; INDUSTRY; STRATEGIC PLANNING;

COMPULSORY LICENSING; DISCRIMINATION PRICES; GLOBAL PRICING STRATEGY; PARALLEL IMPORT;

BIOTECHNOLOGY;

EID: 0035711981     PISSN: 09636048     EISSN: None     Source Type: Journal    
DOI: 10.1504/ijbt.2001.000169     Document Type: Article

References (23)

1. How increased competition from generic has affected prices and returns in the pharmaceutical industry
2. The consequences of pharmaceutical product patenting
3. Retail drug prices: The law of the jungle
4. The uses and abuses of international price comparisons
5. Cross-national price differences for pharmaceuticals: How large and why?
6. Strategic pricing of new pharmaceuticals
7. Price discrimination
8. Price discrimination for pharmaceuticals: Welfare effects in the US and the EU
9. Policy relating to generic competition in the OECD
10. Healthcare and intellectual property: Compulsory licensing
11. South Africa's bitter pill for world's drugs makers
12. The economics of parallel trade
13. South Africa has no intention of undermining patent rights
14. Progress of WHO member states in developing national drug policies and in revising essential drug lists, Geneva, World Health Organization
15. Bristol-Myers heeds calls to bolster the war against HIV in Africa